• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型药物组合伊沙匹隆与卡培他滨对三阴性转移性乳腺癌的持久控制——病例报告

Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.

作者信息

Vrdoljak Eduard, Mise Branka Petrić, Lukić Blanka, Curić Zvonimir, Bosković Lidija, Tica Ivana

机构信息

Center of Oncology, University Hospital Split, Split, Croatia.

出版信息

Onkologie. 2010;33(1-2):53-6. doi: 10.1159/000264615. Epub 2010 Jan 5.

DOI:10.1159/000264615
PMID:20164663
Abstract

BACKGROUND

The optimal duration of ixabepilone and capecitabine chemotherapy combination is currently not known and will most likely be patient-specific based on efficacy, toxicity, quality of life, and patient preference.

CASE REPORT

We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes. Partial remission was achieved, and acceptable toxicity was observed.

CONCLUSIONS

This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer regimen, especially with respect to the optimal duration of its use.

摘要

背景

目前尚不清楚伊沙匹隆与卡培他滨联合化疗的最佳疗程,很可能需根据疗效、毒性、生活质量和患者偏好因人而异。

病例报告

我们报告了1例三阴性转移性乳腺癌患者接受伊沙匹隆与卡培他滨化疗(42个周期)的疗程极长的情况,该患者既往接受过蒽环类药物和紫杉烷类药物治疗。实现了部分缓解,并观察到可接受的毒性。

结论

本报告增加了关于这种重要的新转移性乳腺癌治疗方案应用的知识储备,尤其是在其使用的最佳疗程方面。

相似文献

1
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.新型药物组合伊沙匹隆与卡培他滨对三阴性转移性乳腺癌的持久控制——病例报告
Onkologie. 2010;33(1-2):53-6. doi: 10.1159/000264615. Epub 2010 Jan 5.
2
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.卡培他滨联合伊沙匹隆治疗转移性乳腺癌患者的 Q-TWiST 分析对生活质量的影响。
Cancer. 2012 Jan 15;118(2):461-8. doi: 10.1002/cncr.26213. Epub 2011 May 19.
3
Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.依西美坦联合卡培他滨治疗雌激素受体阴性、孕激素受体阴性和人表皮生长因子受体 2 阴性转移性乳腺癌的疗效
Eur J Cancer. 2009 Nov;45(17):2940-6. doi: 10.1016/j.ejca.2009.07.015. Epub 2009 Aug 13.
4
Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.伊沙匹隆联合卡培他滨治疗蒽环类和紫杉类辅助治疗后早期复发的晚期乳腺癌患者:两项 III 期研究的汇总亚组分析。
Breast. 2012 Feb;21(1):89-94. doi: 10.1016/j.breast.2011.09.003. Epub 2011 Sep 21.
5
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.伊沙匹隆治疗雌激素受体/孕激素受体/人表皮生长因子受体 2 阴性(三阴性)乳腺癌的疗效。
Breast Cancer Res Treat. 2010 Jun;121(2):261-71. doi: 10.1007/s10549-010-0824-0. Epub 2010 Mar 13.
6
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.一项评估口服长春瑞滨联合卡培他滨作为蒽环类和紫杉类药物治疗失败的转移性乳腺癌二线治疗的Ⅱ期临床研究。
Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.
7
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.在对蒽环类和紫杉类耐药的MBC 患者中,进行了一项关于伊沙匹隆联合卡培他滨与卡培他滨的 III 期研究,分析了总生存期。
Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8.
8
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.伊沙匹隆联合卡培他滨及作为单一疗法用于治疗既往化疗难治的晚期乳腺癌。
Clin Cancer Res. 2008 Jul 15;14(14):4378-84. doi: 10.1158/1078-0432.CCR-08-0015.
9
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.伊沙匹隆在局部晚期或转移性乳腺癌患者中的最佳治疗应用。
J Oncol Pharm Pract. 2009 Jun;15(2):95-106. doi: 10.1177/1078155208100095. Epub 2009 Jan 26.
10
Ixabepilone, a new treatment option for metastatic breast cancer.依西美坦,一种转移性乳腺癌的新治疗选择。
Am J Clin Oncol. 2010 Oct;33(5):516-21. doi: 10.1097/COC.0b013e3181b9cd52.

引用本文的文献

1
Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer.奥沙利铂联合S-1治疗晚期三阴性乳腺癌的临床疗效
Exp Ther Med. 2015 Jul;10(1):379-385. doi: 10.3892/etm.2015.2489. Epub 2015 May 12.